Z Gastroenterol 2008; 46(4): 367-375
DOI: 10.1055/s-2007-963637
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

[18F]-FDG-PET in der Diagnostik gastrointestinaler Tumoren

[18F]-FDG-PET in the Diagnostics of Gastrointestinal TumorsI. Buchmann1 , T. M. Ganten2 , U. Haberkorn1
  • 1Abteilung für Nuklearmedizin, Universitätskliniken Heidelberg
  • 2Innere Medizin IV, Gastroenterologie, Universitätsklinik Heidelberg
Weitere Informationen

Publikationsverlauf

Manuskript eingetroffen: 4.9.2007

Manuskript akzeptiert: 4.10.2007

Publikationsdatum:
07. April 2008 (online)

Zusammenfassung

Die Positronenemissionstomografie (PET) mit dem Tracer 2-[18F]-Fluoro-2-desoxy-d-Glukose (FDG) ist ein Verfahren der funktionellen Bildgebung. In der Diagnostik gastrointestinaler Tumoren wird sie bei speziellen Fragestellungen zunehmend eingesetzt. Eine der wichtigsten Domänen der FDG-PET ist hierbei, dass sie beim Ösophagus- und Magenkarzinom frühzeitig den Erfolg einer neoadjuvanten Therapie beurteilen kann: Sie weist sowohl das Therapienansprechen als auch das -versagen frühzeitig nach und ermöglicht, Patientengruppen zu definieren, die von einem Therapiewechsel profitieren. In der Primärdiagnostik des Ösophagus- und Magenkarzinoms ist die FDG-PET bei fortgeschrittenen, lokal jedoch noch resezierbaren Tumoren hilfreich. In kleinen Studien selektierte sie jene Patienten, die einem Stadium IV angehörten und von einer primären Operation wahrscheinlich nicht profitieren. Beim kolorektalen Karzinom ist eine der Hauptindikationen der FDG-PET ebenfalls die Beurteilung des Therapieansprechens. Darüber hinaus ist die FDG-PET insbesondere in der Rezidivdiagnostik hilfreich, um einerseits zwischen Narbe und Tumorrezidiv, insbesondere beim Rektumkarzinom, zu differenzieren und andererseits bei ansteigendem Tumormarker das Rezidiv zu lokalisieren. In der Primärdiagnostik des Kolonkarzinoms werden hepatische und pulmonale Metastasen mit der FDG-PET nachgewiesen. Lymphknotenfiliae hingegen werden zwar mit hoher Spezifität, jedoch nur geringer Sensitivität erkannt. Beim Pankreaskarzinom kann die FDG-PET zur Dignitätsbeurteilung unklarer Raumforderungen des Pankreas und in der Rezidivdiagnostik eingesetzt werden. Bei gastrointestinalen Stromatumoren gewinnt die FDG-PET in der Beurteilung des Therapienansprechens und im initialen Staging neben der CT an Bedeutung. Primäre Leber- und Gallenblasenkarzinome werden mit der FDG-PET nur unzureichend abgebildet.

Abstract

Positron emission Tomography (PET) with 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) is a functional imaging technique with increasing value in special diagnostic fields of gastrointestinal tumours. In the initial staging of esophageal and gastric cancer, FDG-PET is useful in the staging of patients with advanced but local resectable disease. The detection of distant metastases results in an up-staging, and these patients should not be treated by surgery. Furthermore, FDG-PET is sufficient for monitoring early therapy responses after neoadjuvant treatment and enables one to select non-responders who may benefit from therapy alterations. Major indications for FDG-PET in patients with rectal carcinoma are therapy monitoring and diagnosis of relapses, especially the differentiation between tumour and scar and also the localisation of tumour manifestations in cases with increasing tumour markers. FDG-PET is very efficient in the imaging of pulmonal and hepatic metastases of colorectal cancer but not in lymph node staging. In diagnostic procedures for pancreatic carcinoma, FDG-PET can be recommended to explore the dignity of pancreatic lesions and in the imaging of tumour relapses. For gastrointestinal stroma tumours, FDG-PET is useful for the monitoring of therapy and the initial staging. For imaging of hepatocellular carcinoma and carcinoma of the gall bladder, FDG-PET is not sufficient.

Literatur

  • 1 Warburg O. On the origins of cancer cells.  Science. 1956;  123 309-314
  • 2 Som P, Atkins H L, Bandoypadhyay D. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose [F-18]: Nontoxic tracer for rapid tumor detection.  J Nucl Med. 1980;  21 670-675
  • 3 Zimny M, Bares R, Fass J. et al . Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma : A report of 106 cases.  Eur J Nucl Med. 1997;  24 678-682
  • 4 Tio T L, Coene P P, den Hartog Jager F C. et al . Preoperative TNM classification of esophageal carcinoma by endosonography.  Hepato-gastroenterology. 1990;  37 (4) 376-381
  • 5 Ziegler K, Sanft C, Zeitz M. et al . Evaluation of endosonography in TN staging of oesophageal cancer.  Gut. 1991;  32 (1) 16-20
  • 6 Buchmann I, Hansen T, Brochhausen C. et al . The value of FDG-PET in the initial staging of squamous cell esophageal carcinoma.  Nucl Med. 2006;  45 (6) 235
  • 7 Yuan S H, Yu J M, Yu Y H. et al . [FDG] PET/CT versus PET alone for pre-surgical detection of lymph node metastasis in esophageal carcinoma.  Zhonghua Zhong Liu Za Zhi. 2007;  29 221-224
  • 8 Westerterp M, Westreenen H L, Reitsma J B. et al . Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review.  Radiology. 2005;  236 (3) 841-851
  • 9 Konski van A, Doss M, Milestone B. et al . The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma.  Int J Radiat Oncol Biol Phys. 2005;  61 1123-1128
  • 10 Kato H, Miyazaki T, Nakajima M. et al . Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.  Br J Surg. 2004;  91 (8) 1004-1009
  • 11 Flanagan F L, Dehdashti F, Siegel B A. et al . Staging of esophageal cancer with [F-18]fluorodeoxyglucose positron emission tomography.  AJR Am J Roentgenol. 1997;  168 417-424
  • 12 Block M I, Pattersen G A, Sundaresan R S. et al . Improvement in staging of esophageal cancer with the addition of positron emission tomography.  Ann Thorac Surg. 1997;  64 770-776
  • 13 Choi J Y, Lee K H, Shim Y M. et al . Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG-PET.  J Nucl Med. 2000;  41 808-815
  • 14 Yeung H WD, Macapinlac H A, Mazumdar M. et al . FDG-PET in esophageal cancer: incremental value over Computer tomography.  Clin Positron Imaging. 1999;  2 255
  • 15 Luketich, Friedman D M, Weigel T L. et al . Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans.  Ann Thorac Surg. 1999;  68 1133-1136
  • 16 Cunningham D, Allum W H, Stenning S P. et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.  N Engl J Med. 2006;  355 11-18
  • 17 Yamada A, Oguchi K, Fukushima M. et al . Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: Relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression.  Ann Nucl Med. 2006;  20 (9) 597-604
  • 18 Mukai K, Ishida Y, Okajima K. et al . Usefulness of preoperative FDG-PET for detection of gastric cancer.  Gastric cancer. 2006;  9 (3) 192-196
  • 19 Kim S K, Kang K W, Lee J S. et al . Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer.  Eur J Nucl Med Mol Imaging. 2006;  33 (2) 148-155
  • 20 Ott K, Weber W A, Lordick F. et al . Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.  J Clin Oncol. 2006;  24 (29) 4692-4698
  • 21 Lordick F, Ott K, Krause B J. et al . PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.  Lancet Oncol. 9.8.2007; [Epub ahead of print]; 
  • 22 De Potter T, Flamen P, Van Cutsem E. et al . Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.  Eur J Nucl Med Mol Imaging. 2002;  29 (4) 525-529
  • 23 Yun M, Lim J S, Noh S H. et al . Lymph node staging of gastric cancer using (18)F-FDG PET: A comparison study with CT.  J Nucl Med. 2005;  46 (10) 1582-1588
  • 24 Chen Y K, Kao C H, Liao C H. et al . Colorectal cancer screening in asymptomatic adults: The role of FDG PET scan.  Anticanc Res. 2003;  23 (5b) 4357-4361
  • 25 Drenth J P, Nagengast F M, Oyen W J. Evaluation of (pre-)malignant Kolonic abnormalities: endoscopic validation of FDG-PET findings.  Eur J Nucl Med Mol Imaging. 2001;  28 1766-1769
  • 26 Abdel-Nabi H, Doerr R J, Lamonica D M. et al . Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings.  Radiology. 1998;  206 (3) 755-760
  • 27 Schlag P M, Amthauer H, Stroszczynski C. et al . Influence of positron emission tomography on surgical therapy planning in recurrent colorectal cancer.  Chirurg. 2001;  72 (9) 995-1002
  • 28 Staib L, Schirrmeister H, Reske S N. et al . Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?.  Am J Surg. 2000;  180 (1) 1-5
  • 29 Gupta N C, Falk P M, Frank A L. et al . Pre-operative staging of colorectal carcinoma using positron emission tomography.  Nebr Med. 1993;  J 78 30
  • 30 Zhuang H, Sinha P, Purdehnad M. et al . The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to the liver.  Nucl Med Comm. 2000;  21 (9) 793-798
  • 31 Haberkorn U, Strauss L G, Dimitrakopolou A. et al . PET studies of fluordodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy.  J Nucl Med. 1991;  32 1485-1490
  • 32 Schiepers C, Penninckx F, Vadder N de. et al . Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging.  Eur J Surg Oncol. 1995;  21 517
  • 33 Valk P E, Abella-Columna E, Haseman M K. et al . Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.  Arch Surg. 1999;  134 (5) 503-511
  • 34 Huebner R H, Park J E, Shepard J E. et al . A meta-analysis of the literature for whole body FDG-PET in the detection of recurrent colorectal cancer.  J Nucl Med. 2000;  41 1177-1189
  • 35 Delbeke D, Vitola J V, Sandler M P. et al . Staging recurrent metastatic colorectal carcinoma with PET.  J Nucl Med. 1997;  38 1196-1200
  • 36 Vitola J V, Delbeke D, Sandler M P. et al . Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.  Am J Surg. 1996;  171 21
  • 37 Lai D T, Fulham M, Stephen M S. et al . The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal metastases to the liver.  Arch Surg. 1996;  131 (7) 703-707
  • 38 Flanagan F L, Dehdashti F, Ogunbiyi O A. et al . Utility of FDG-PET for investigating unexplained plasma CEA level elevation in patients with colorectal cancer.  Ann Surg. 1998;  227 319
  • 39 Tutt A NJ, Plunkett T A, Barrington S F. et al . The role of positron emission tomography in the management of colorectal cancer.  Colorectal Dis. 2004;  6 2-9
  • 40 Kalff V V, Hicks R, Ware R. et al . F-18 FDG PET for suspected or confirmed regional recurrence of Kolon cancer. A prospective study of impact and outcome.  Clin Positron Imaging. 2000;  3 (4) 183
  • 41 Adler G, Seufferlein T, Bischoff S C. et al . S3-Leitlinie „Exokrines Pankreaskarzinom” 2007.  Z Gastroenterol. 2007;  45 487-523
  • 42 Reske S N, Kotzerke J. FDG-PET for clinical use. Results of the 3 rd German Interdisciplinary Consensus Conference „Onco-PET III”, 21 July and 19 September 2000.  Eur J Nucl Med Mol Imaging. 2001;  28 1707-1723
  • 43 Inokuma T, Tamaki N, Torizuka T. et al . Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.  Radiology. 1995;  195 345-352
  • 44 Friess H, Langhans J, Ebert M. et al . Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.  Gut. 1995;  36 771-777
  • 45 Stollfuss J C, Glatting G, Friess H. et al . 2- (Fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.  Radiology. 1995;  195 339-344
  • 46 Delbeke D, Rose D M, Chapman W C. et al . Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.  J Nucl Med. 1999;  40 1784-1791
  • 47 Imdahl A, Nitzsche E, Krautmann F. et al . Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.  Br J Surg. 1999;  86 194-199
  • 48 Nakamoto Y, Higashi T, Sakahara H. et al . Delayed 18F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.  Cancer. 2000;  89 2547-2554
  • 49 Diederichs C G, Staib L, Vogel J. et al . Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses.  Pancreas. 2000;  20 109-116
  • 50 Koyama K, Okamura T, Kawabe J. et al . Diagnostic usefulness of FDG-PET for pancreatic mass lesions.  Ann Nucl Med. 2001;  15 217-224
  • 51 Papos M, Takacs T, Tron L. et al . The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions.  Clin Nucl Med. 2002;  27 197-201
  • 52 Van Kouwen M CA, Jansen J BMJ, Goor van H. et al . FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis.  Eur J Nucl Med. 2005;  32 399-404
  • 53 Gambhir S S, Szernin J, Schwimmer J. et al . A tabulated summary of the FDG PET literature.  J Nucl Med. 2001;  42 1S-93S
  • 54 Sperti C, Pasquali C, Chierichetti F. et al . Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas.  Ann Surg. 2001;  234 675-680
  • 55 Bares R, Klever P, Hauptmann S. et al . F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.  Radiology. 1994;  192 79-86
  • 56 Sperti C, Pasquali C, Decet G. et al . F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: A prospective study.  J Gastrointest Surg. 2005;  9 22-28, discussion 28 - 29
  • 57 Bang S, Chung H W, Park S W. et al . The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.  J Clin Gastroenterol. 2006;  40 (10) 923-929
  • 58 Ruf J, Lopez Hanninen E, Oettle H. et al . Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI.  Pancreatology. 2005;  5 266-272
  • 59 Llovet J, Ricci S, Mazzaferro V. et al . Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial).  Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007;  Vol 25, No. 18S (Suppl) LBA1
  • 60 Trojan J, Schroeder O, Raedle J. et al . Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.  Am J Gastroenterol. 1999;  94 (11) 3314-3319
  • 61 Khan M A, Combs C S, Brunt E M. et al . Positron emission tomography scanning in the evaluation of hepatocellular carcinoma.  J Hepatol. 2000;  32 (5) 792-979
  • 62 Sugiyama M, Sakahara H, Torizuka T. et al . 18F-FDG-PET in the detection of extrahepatic metatsases from hepatocellular carcinoma.  J Gastroenterol. 2004;  39 (10) 961-968
  • 63 Anderson C D, Rice M H, Pinson C W. et al . Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma.  J Gastrointest Surg. 2004;  8 90-97
  • 64 Kluge R, Schmidt F, Caca K. et al . Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.  Hepatology. 2001;  33 1029-1035
  • 65 Bertin M, Angriman I, Scarpa M. et al . Prognosis of gastrointestinal stromal tumors.  Hepatogastroenterology. 2007;  54 (73) 124-128
  • 66 Weber A G, Jovenin N, Lubrano D. Outcome after surgical treatment of gastrointestinal stromal tumors.  Gastroenterol Clin Biol. 2007;  31 (6 - 7) 579-584
  • 67 Gayed I, Vu T, Iyer R. et al . The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.  J Nucl Med. 2004;  45 17-21
  • 68 Alzahouri K, Lejeune C, Woronoff-Lemsi M C. et al . Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.  Clin Radio. 2005;  60 (4) 479-492
  • 69 Heinrich S, Goerres G W, Schafer M. et al . Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.  Ann Surg. 2005;  242 (2) 235-243
  • 70 Kalvin B, Fekeshazy A, Lengyel Z. et al . Cost-effective PET investigations in oncology.  Magy Onkol. 2002;  46 (3) 203-223
  • 71 Sloka J S, Hollett P D. Cost effectiveness of positron emission tomography in Canada.  Med Sci Moni. 2005;  11 (10) PH1-6
  • 72 Zubeldia J M, Bednarczyk E M, Baker J G. et al . The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases.  Cancer Biother Radiopharm. 2005;  20 (4) 450-456

Dr. Inga Buchmann

Abteilung für Nuklearmedizin, Universitätskliniken Heidelberg

Im Neuenheimer Feld 400

69120 Heidelberg

Telefon: ++ 49/62 21/5 63 94 61

eMail: inga.buchmann@med.uni-heidelberg.de